Solural Pharma ApS publish clinical results for its oral irinotecan product in combination with capecitabine in Cancer Chemotherapy and Pharmacology: An open label phase 1 study evaluating safety, tolerability and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine
- New patent acquisition agreement November 16, 2022
- New Eurasia patent December 25, 2020
- New Manufacturing Authorisation December 18, 2020
If you are interested in joining Solural Pharma ApS, we are seeking professionals, technicians and consultants with expertise within drug development. Please contact
firstname.lastname@example.org for more information about available positions.